Ikarian Capital LLC Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Ikarian Capital LLC lowered its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 47.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,175 shares of the company’s stock after selling 50,000 shares during the period. Ikarian Capital LLC owned about 0.37% of Jasper Therapeutics worth $1,038,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its position in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in Jasper Therapeutics in the third quarter worth $59,000. MetLife Investment Management LLC boosted its position in Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares during the last quarter. Rhumbline Advisers purchased a new position in Jasper Therapeutics in the second quarter worth $300,000. Finally, American Century Companies Inc. raised its stake in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after buying an additional 3,032 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on JSPR shares. Royal Bank of Canada lowered their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. JMP Securities restated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Evercore ISI restated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has an average rating of “Buy” and a consensus target price of $74.86.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR traded up $1.13 during midday trading on Tuesday, reaching $25.10. 27,850 shares of the company traded hands, compared to its average volume of 175,084. Jasper Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $31.01. The firm’s fifty day moving average price is $20.28 and its two-hundred day moving average price is $20.92.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.